Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 18, 2009
MannKind
Corporation
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-50865
|
|
13-3607736
|
(State
or other jurisdiction of
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
incorporation)
|
|
|
|
Identification
No.)
|
|
|
|
28903
North Avenue Paine
|
|
|
Valencia,
California
|
|
91355
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, Including Area Code: (661) 775-5300
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 8.01
Other Events
On May
18, 2009, MannKind Corporation announced that the U.S. Food and Drug
Administration has accepted and filed MannKind’s New Drug Application for
AFRESA®, an
ultra rapid-acting insulin. MannKind is seeking FDA approval of
AFRESA for the treatment of adults with type 1 or type 2 diabetes mellitus for
the control of hyperglycemia.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
MANNKIND
CORPORATION
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/
MATTHEW J. PFEFFER
|
|
|
|
|
Name:
|
|
Matthew
J. Pfeffer
|
|
|
|
|
Title:
|
|
Corporate
Vice President and Chief
|
|
|
|
|
|
|
Financial
Officer
|
|
Dated:
May 18, 2009